Comparative Evaluation of Cisplatin and Carboplatin Sensitivity in Endometrial Adenocarcinoma Cell Lines
Author Information
Author(s): V. Rantanen, S. Grenman, J. Kulmala, R. Grenman
Primary Institution: University of Turku
Hypothesis
What is the sensitivity of endometrial adenocarcinoma cell lines to cisplatin and carboplatin?
Conclusion
The study found considerable variability in the sensitivity of endometrial adenocarcinoma cell lines to cisplatin and carboplatin.
Supporting Evidence
- The IC50 values for cisplatin varied between 0.022 and 0.56 µg/ml.
- The IC50 values for carboplatin ranged from 0.096 to 1.20 µg/ml.
- The mean IC50 values were 0.23 µg/ml for cisplatin and 0.50 µg/ml for carboplatin.
- There was a 25-fold difference in sensitivity among the cell lines for cisplatin.
Takeaway
This study tested how well different endometrial cancer cell lines respond to two drugs, cisplatin and carboplatin, and found that some cells are much more resistant than others.
Methodology
The study used a 96-well-plate clonogenic assay to test the sensitivity of eight endometrial adenocarcinoma cell lines to cisplatin and carboplatin.
Limitations
In vitro studies may not fully represent in vivo responses, and the study only included a limited number of cell lines.
Want to read the original?
Access the complete publication on the publisher's website